Topical aminolevulinic acid HCl photodynamic therapy

American Journal of Clinical Dermatology

Volumn 1, Issue 2, 2000, Pages 133-139

  Ormrod, Douglas ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; PHOTOSENSITIZING AGENT;

HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AMINOLEVULINIC ACID; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 0034158013     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001020-00009     Document Type: Article

References (42)

1. Ash DV, Brown SB. New drugs and future developments in photodynamic therapy. Eur J Cancer 1993; 29A: 1781-3
2. McCaughan JS Jr. Photodynamic therapy. A review. Drugs Aging 1999; 15 (1): 49-68
3. Product information: Levulan R Kerastick TM (aminolevulinic acid HCl) for topical solution, 20 %. Dusa Pharmaceutical, Inc., Vahalla, New York, NY, USA; 1999
4. Stables GI, Ash DV. Photodynamic therapy. Cancer Treat Rev 1995 Jul; 21: 311-23
5. Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology. Arch Dermatol 1998 Feb; 134: 207-14
6. Roberts DJ, Cairnduff F. Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg 1995 Sep; 48: 360-70
7. Frost CA, Green AC. Epidemiology of solar keratosis. Br J Dermatol 1994; 131: 455-64
8. Barnaby JWJ, Styles AR, Cockerell CJ. Actinic keratoses: differential diagnosis and treatment. Drugs Aging 1997 Sep; 11: 186-205
9. Fink-Puches R, Hofer A, Smolle J, et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B 1997 Nov; 41: 145-51
10. Jeffes E, McCullough J, Weinstein G, et al. Photodynamic therapy of patients having multiple actinic keratoses with topical 5-aminolevulinic acid and non-laser blue light [abstract]. J Invest Dermatol 1998 Apr; 110: 680
11. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995 Jul; 29: 53-7
12. Szeimies RM, Karrer S, Sauerwald A, et al. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 1996; 192 (3): 246-51
13. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose-ranging study. Arch Dermatol 1997 Jun; 133: 727-32
14. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferrioxamine. Br J Dermatol 1995 Aug; 133: 282-8
15. Karrer S, Abels C, Bauaumler W, et al. Topical photodynamic therapy with 5-aminolevulinic acid for actinic keratoses using the Sclerolaser (Rm) at 585 NM. J Invest Dermatol 1998 Apr; 110: 679
16. Food and Drug Administration Center for Drug Evaluation and Research. Dermatologic and Opthalmic Drugs Advisory Committee Open Session: NDA 20-965 Levulan Kerastick for Topical Solution, 1999 Nov 5. Food and Drug Administration, 1999. Available from: http://www.fda.gov/ohrms/dockets/ac/99/trans-cpt/3564t2.pdf [Accessed 1999 Jan 20]
17. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 1996 Oct; 14: 289-304
18. Radakovic-Fijan S, Rappersberger K, Tanew A, et al. Ultrastructural changes in PAM cells after photodynamic treatment with delta-aminolevulinic acid-induced porphyrins or photosan. J Invest Dermatol 1999 Mar; 112: 264-70
19. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990 Jun; 6: 143-8
20. Fritsch C, Stege H, Saalmann G, et al. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photodermatol Photoimmunol Photomed 1997 Oct-Dec; 13: 181-5
21. van-den-Boogert J, van-Hillegersberg R, de-Rooij FW, et al. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B 1998 Jun 15; 44: 29-38
22. Heyerdahl H, Wang I, Liu DL, et al. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett 1997 Jan 30; 112: 225-31
23. Fritsch C, Batz J, Bolsen K, et al. Ex vivo application of delta-aminolevulinic acid induces high and specific porphyrin levels in human skin tumors: possible basis for selective photodynamic therapy. Photochem Photobiol 1997 Jul; 66: 114-8
24. Stringer MR, Collins P, Robinson DJ, et al. The accumulation of protoporphyrin IX in plaque psoriasis alter topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J Invest Dermatol 1996 Jul; 107: 76-81
25. Hanania J, Malik Z. The effect of EDTA and serum on endogenous porphyrin accumulation and photodynamic sensitization of human K562 leukemic cells. Cancer Lett 1992 Aug 14; 65: 127-31
26. Ortel B, Tanew A, Honigsmann H. Lethal photosensitization by endogenous porphyrins of PAM cells-modification by desferrioxamine. J Photochem Photobiol B 1993 Mar; 17: 273-8
27. Langer S, Abels C, Botzlar A, et al. Active and higher intracellular uptake of 5-aminolevulinic acid in tumors may be inhibited by glycine. J Invest Dermatol 1999 May; 112: 723-8
28. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical reseacrh and future challenges. Cancer 1997 Jun 15; 79: 2282-308
29. Rick K, Sroka R, Stepp H, et al. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. J Photochem Photobiol B 1997 Oct; 40: 313-9
30. Fritsch C, Verwohlt B, Bolsen K, et al. Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. Arch Dermatol Res 1996 Aug; 288: 517-21
31. Bretschko E, Szeimies RM, Landthaler M, et al. Topical 5-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Evaluation of stratum comeum permeability in vitro. J Control Release 1996 Dec; 42: 203-8
32. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992 Jul 30; 14: 275-92
33. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol 1993 Jan; 28: 17-21
34. Levulan R Kerastick TM. NDA aplication to FDA number 20-965, 12 July 1999. Data on file, Dusa Pharmaceuticals Inc., Valhalla, New York, NY, USA
35. Orenstein A, Kostenich G, Tsur H, et al. Temperature monitoring during photodynamic therapy of skin tumors with topical 5-aminolevulinic acid application. Cancer Lett 1995 Jul 13; 93: 227-32
36. Gniazdowska B, Rueff F, Hillemanns P, et al. Allergic contact dermatitis from delta-aminolevulinic acid used for photodynamic therapy. Contact Dermatitis 1998 Jun; 38: 348-9
37. Wolf P, Fink-Puches R, Reimann-Weber A, et al. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 1997; 194 (1): 53-4
38. Stender IM, Wulf HC. Kobner reaction induced by photodynamic therapy-using delta-aminolevulinic acid. A case report. Acta Derm Venereol 1996 Sep; 76: 392-3
39. Fiedler DM, Eckl PM, Krammer B. Does delta-aminolaevulinic acid induce genotoxic effects? J Photochem Photobiol B 1996 Mar; 33: 39-44
40. Jahan MA, Tait IS, Newman EL, et al. Is 5-aminolaevulinic acid a safe photosensitiser? [abstract]. Gut 1998 Mar; 42 Suppl. 1:51
41. Venwanger T, Schnitzhofer G, Krammer B. Expression kinetics of the (proto) oncogenes c-myc and bel-2 following photodynamic treatment of normal and transformed human fibroblasts with 5-aminolaevulinic acid-stimulated endogenous protoporphyrin IX. J Photochem Photobiol B 1998 Sep; 45: 131-5
42. Whetsell WO Jr, Sassa S, Kappas A. Porphyrin-heme biosynthesis in organotypic cultures of mouse dorsal root ganglia. Effects of heme and lead on porphyrin synthesis and peripheral myelin. J Clin Invest 1984 Aug; 74: 600-7